Tag: Revive Therapeutics Ltd.

April 3, 2020

Revive Therapeutics Announces Filing of FDA Pre-IND Meeting

Revive Therapeutics (CSE:RVV) has filed its pre-IND meeting request with the U.S. FDA for Bucillamine in the treatment of COVID-19.
April 3, 2020

Revive Therapeutics Provides An Investor Announcement

Revive Therapeutics (CSE:RVV), a life sciences company, has learnt that buy recommendations and letters are being circulated in Germany.
March 30, 2020

Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs

Revive Therapeutics is pleased to provide a corporate update on its plans for the Company’s COVID-19 and infectious diseases programs.
March 24, 2020

Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19

Revive Therapeutics (CSE:RVV) is pleased to announce that Dr. David Boulware, MD, MPH, CTropMed, FIDSA, will join the Company as...
March 20, 2020

Revive Therapeutics Explores the use of Bucillamine as a Novel Treatment for Infectious Diseases Including COVID-19

Revive Therapeutics is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza...
March 18, 2020

Revive Therapeutics Announces Closing of Brokered Private Placement

Revive Therapeutics (CSE:RVV) is pleased to announce that further to its press release of February 11, 2020, it has closed...
March 6, 2020

Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.

Revive Therapeutics Ltd. has completed its acquisition of all of the issued and outstanding securities in the capital of Psilocin...